Abstract

Chitosan oligosaccharides (COS) have shown positive effects on host gut health and influence on intestinal microbial community. However, the bioactivity and mechanism of COS on gut microbiota is still poorly understood. Here, we presented systematic studies of COS on mice fecal/gut microbiota. During in vitro fermentation of COS by mice gut microbiota, total bacterial population significantly decreased after 8-h COS treatment but was returned to the normal level after extended incubation. Consumption of COS and production of SCFAs suggested that COS were utilized by the microbe, although the consumption of chitosan pentasaccharides was obviously slower than others. COS treatments on mice fecal samples caused the decrease of potential pathogenic genera Escherichia/Shigella and the increase of genus Parabacteroides. In vivo animal study indicated that COS reduced population of probiotic genera Lactobacillus, Bifidobacterium and harmful genus Desulfovibrio, and increased abundance of genus Akkermansia. Phylum Proteobacteria was significantly inhibited by COS both in the animal model and in vitro fermentation. Our findings suggested that COS could reform the community structure of gut microbiota. The relationship among COS, gut microbiota and host health deserve further study.

Highlights

  • Chitin the second most abundant biopolymer in the world

  • The change of Chitosan oligosaccharides (COS) was not recorded in samples treated with 0.1 g L−1 COS since the concentration was below the detection limit of the high performance liquid chromatography (HPLC) instrument used in the experiment

  • The utilization rate was different among COS oligomers, in which COS-5 was obviously not favored by the fecal microbe

Read more

Summary

Introduction

Chitin the second most abundant biopolymer in the world. Chitosan oligosaccharides (COS), a mixture of oligomers of beta-1, 4-linked D-glucosamine, are prepared from chitosan, a N-deacetylated derivative is of chitin (Thadathil and Velappan, 2014). Chitosan Oligosaccharides Affect Gut Microbiota the human genome encodes, at most, only 17 enzymes for the digestion of food glycans, starch, sucrose, and lactose and no polysaccharide lyases (Cantarel et al, 2012). COS as potential non-digestible oligosaccharides for the host, could be metabolized by gut microbiota. Various studies reported that supplementation of COS significantly increased the abundance of Escherichia spp. in rats (Shang et al, 2017), but decreased the relative abundance of Lactobacillus in weanling pigs (Yu et al, 2017). Supplementation of COS and resistant starch mixtures alleviated metabolic disorders through synergistic actions, including positive manipulations on gut microbiota, lipid metabolism, and thickness of colonic mucosa layer in the rat (Shang et al, 2017)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call